Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicotinic acid effect on HDL composition and endothelial function in premature coronary heart disease with elevated HDL-cholesterol
2011-000755-17Phase 3Terminated
- Sponsor
- Xavier Pintó Sala
- Start
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of laropiprant in Chronic Coronary Syndrome (CCS), sponsored by Xavier Pintó Sala. Primary endpoints: Change in HDL composition and Change in endothelial function. Started Oct 2011; status: terminated.
02
Drugs
laropiprant
03
Conditions
Chronic Coronary Syndrome (CCS)
Beyond the preview
Go deeper on 2011-000755-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000755-17.